SG11201906435SA - Pyrimidine compound and pharmaceutical use thereof - Google Patents
Pyrimidine compound and pharmaceutical use thereofInfo
- Publication number
- SG11201906435SA SG11201906435SA SG11201906435SA SG11201906435SA SG11201906435SA SG 11201906435S A SG11201906435S A SG 11201906435SA SG 11201906435S A SG11201906435S A SG 11201906435SA SG 11201906435S A SG11201906435S A SG 11201906435SA SG 11201906435S A SG11201906435S A SG 11201906435SA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrimidine compound
- pharmaceutical use
- pyrimidine
- cancer
- prevention
- Prior art date
Links
- -1 Pyrimidine compound Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170012766 | 2017-01-26 | ||
| PCT/KR2018/001193 WO2018139903A1 (fr) | 2017-01-26 | 2018-01-26 | Composé pyrimidine et son utilisation pharmaceutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906435SA true SG11201906435SA (en) | 2019-08-27 |
Family
ID=62979563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906435SA SG11201906435SA (en) | 2017-01-26 | 2018-01-26 | Pyrimidine compound and pharmaceutical use thereof |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US10280154B2 (fr) |
| EP (2) | EP3789386A1 (fr) |
| JP (3) | JP6608565B2 (fr) |
| KR (1) | KR101954369B1 (fr) |
| CN (1) | CN110214138A (fr) |
| AR (1) | AR110778A1 (fr) |
| AU (1) | AU2018211880B2 (fr) |
| BR (1) | BR112019015256A2 (fr) |
| CA (1) | CA3050239A1 (fr) |
| DK (1) | DK3514153T3 (fr) |
| EA (1) | EA039868B1 (fr) |
| ES (1) | ES2890668T3 (fr) |
| HU (1) | HUE056472T2 (fr) |
| IL (2) | IL290745B2 (fr) |
| MX (1) | MX2019008808A (fr) |
| PH (1) | PH12019501690A1 (fr) |
| PL (1) | PL3514153T3 (fr) |
| PT (1) | PT3514153T (fr) |
| SA (1) | SA519402288B1 (fr) |
| SG (1) | SG11201906435SA (fr) |
| TW (1) | TWI810172B (fr) |
| WO (1) | WO2018139903A1 (fr) |
| ZA (1) | ZA201905020B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018139903A1 (fr) * | 2017-01-26 | 2018-08-02 | 한미약품 주식회사 | Composé pyrimidine et son utilisation pharmaceutique |
| AU2019203034B1 (en) * | 2018-07-25 | 2019-09-26 | Hanmi Pharm. Co., Ltd. | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same |
| KR101954370B1 (ko) * | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| PE20212153A1 (es) | 2019-02-22 | 2021-11-09 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda |
| SG11202108867VA (en) * | 2019-02-22 | 2021-09-29 | Hanmi Pharmaceutical Co Ltd | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
| WO2020171649A1 (fr) * | 2019-02-22 | 2020-08-27 | 한미약품 주식회사 | Combinaison pharmaceutique comprenant un inhibiteur flt3 et un antagoniste iap pour le traitement de la leucémie myéloïde aiguë |
| CN111606889B (zh) * | 2019-02-25 | 2023-03-07 | 上海翰森生物医药科技有限公司 | 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法 |
| EA202290154A1 (ru) | 2019-06-27 | 2022-03-29 | Ханми Фарм. Ко., Лтд. | Фармацевтическая композиция для лечения острого миелоидного лейкоза, содержащая ингибитор flt3 и химиотерапевтические агенты |
| CN116940565A (zh) * | 2021-01-07 | 2023-10-24 | 安大略省癌症研究所(Oicr) | 作为nuak激酶的抑制剂的异吲哚啉酮氨基嘧啶化合物、其组合物和用途 |
| WO2023082052A1 (fr) * | 2021-11-09 | 2023-05-19 | 暨南大学 | Composé de 2-aminopyrimidine cyclique et son application |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0500492D0 (en) * | 2005-01-11 | 2005-02-16 | Cyclacel Ltd | Compound |
| US20110183975A1 (en) * | 2008-10-07 | 2011-07-28 | Yasuhiro Goto | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| CN101723936B (zh) | 2008-10-27 | 2014-01-15 | 上海睿星基因技术有限公司 | 激酶抑制剂及其在药学中的用途 |
| US20100105655A1 (en) | 2008-10-29 | 2010-04-29 | Astrazeneca Ab | Novel compounds 515 |
| US20110005173A1 (en) * | 2009-07-08 | 2011-01-13 | Kraft Foods Global Brands Llc | Method and Apparatus to Create a Contoured Flow Wrap Package |
| CN102471339A (zh) * | 2009-07-15 | 2012-05-23 | 雅培制药有限公司 | 激酶的吡咯并吡啶抑制剂 |
| TW201219383A (en) * | 2010-08-02 | 2012-05-16 | Astrazeneca Ab | Chemical compounds |
| ES2900230T3 (es) | 2011-07-27 | 2022-03-16 | Astrazeneca Ab | Compuestos de 2-(2,4,5-anilino sustituido)pirimidina |
| EP2832734A4 (fr) * | 2012-03-28 | 2015-08-26 | Takeda Pharmaceutical | Composé hétérocyclique |
| WO2014155300A2 (fr) * | 2013-03-28 | 2014-10-02 | Aurigene Discovery Technologies Limited | Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1 |
| EP3489232A3 (fr) * | 2014-04-04 | 2019-07-31 | Syros Pharmaceuticals, Inc. | Inhibiteurs de la kinase cycline-dépendante 7 (cdk7) |
| WO2016029839A1 (fr) * | 2014-08-25 | 2016-03-03 | 四川海思科制药有限公司 | Dérivé aminé (subtitué phényle) (substitué pyrimidine), son procédé de préparation, et utilisation comme médicament |
| CN115925693A (zh) * | 2017-01-17 | 2023-04-07 | 阿斯利康(瑞典)有限公司 | Jak1选择性抑制剂 |
| WO2018139903A1 (fr) | 2017-01-26 | 2018-08-02 | 한미약품 주식회사 | Composé pyrimidine et son utilisation pharmaceutique |
-
2018
- 2018-01-26 WO PCT/KR2018/001193 patent/WO2018139903A1/fr unknown
- 2018-01-26 MX MX2019008808A patent/MX2019008808A/es unknown
- 2018-01-26 EA EA201991580A patent/EA039868B1/ru unknown
- 2018-01-26 ES ES18744290T patent/ES2890668T3/es active Active
- 2018-01-26 HU HUE18744290A patent/HUE056472T2/hu unknown
- 2018-01-26 EP EP20201112.8A patent/EP3789386A1/fr not_active Withdrawn
- 2018-01-26 BR BR112019015256A patent/BR112019015256A2/pt active Search and Examination
- 2018-01-26 CA CA3050239A patent/CA3050239A1/fr active Pending
- 2018-01-26 IL IL290745A patent/IL290745B2/en unknown
- 2018-01-26 PL PL18744290T patent/PL3514153T3/pl unknown
- 2018-01-26 DK DK18744290.0T patent/DK3514153T3/da active
- 2018-01-26 AU AU2018211880A patent/AU2018211880B2/en active Active
- 2018-01-26 SG SG11201906435SA patent/SG11201906435SA/en unknown
- 2018-01-26 JP JP2019519419A patent/JP6608565B2/ja active Active
- 2018-01-26 KR KR1020180010226A patent/KR101954369B1/ko active IP Right Grant
- 2018-01-26 PT PT187442900T patent/PT3514153T/pt unknown
- 2018-01-26 CN CN201880008683.1A patent/CN110214138A/zh active Pending
- 2018-01-26 AR ARP180100179A patent/AR110778A1/es unknown
- 2018-01-26 TW TW107102879A patent/TWI810172B/zh active
- 2018-01-26 EP EP18744290.0A patent/EP3514153B1/fr active Active
- 2018-09-11 US US16/127,487 patent/US10280154B2/en active Active
- 2018-12-19 US US16/226,070 patent/US10519141B2/en active Active
-
2019
- 2019-07-11 IL IL268010A patent/IL268010B/en unknown
- 2019-07-23 PH PH12019501690A patent/PH12019501690A1/en unknown
- 2019-07-24 SA SA519402288A patent/SA519402288B1/ar unknown
- 2019-07-30 ZA ZA2019/05020A patent/ZA201905020B/en unknown
- 2019-10-23 JP JP2019192510A patent/JP7191799B2/ja active Active
-
2022
- 2022-12-07 JP JP2022195974A patent/JP2023027203A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519402288B1 (ar) | مركب بيريميدين واستخداماته الصيدلانية | |
| PH12019501688A1 (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
| GEP20207161B (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| ZA202100485B (en) | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | |
| GEP20207160B (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| GEP20217211B (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
| PH12019501955A1 (en) | Tri-cycle compound and applications thereof | |
| TN2019000211A1 (en) | Antitumoral compounds | |
| MX2020005659A (es) | Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia. | |
| MX2021012096A (es) | Compuestos de indenilo, composiciones farmaceuticas y usos medicos del mismo. | |
| PH12020550403A1 (en) | Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof | |
| MX2016010877A (es) | Amidas antimitoticas para el tratamiento del cancer y desordenes proliferativos. | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| PH12017501955A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease | |
| WO2018211324A8 (fr) | Promédicaments pour traiter une maladie | |
| MX2018015269A (es) | Derivados de tailanstatina a, metodos de tratamiento y metodos de sintesis de los mismos. | |
| PH12018501100A1 (en) | Phenylimidazole compound | |
| MX2019005504A (es) | Potenciadores de bmp. | |
| MX2019005090A (es) | Derivados de piridazina como moduladores de receptor gamma huerfano relacionado a acido retinoico (rorc). | |
| MX2022006984A (es) | Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina. |